Reducción de la morbimortalidad cardiovascular tras un episodio cardiovascular agudo mediante el tratamiento intensivo de los factores de riesgo (proyecto MIRVAS)

Moreno Palanco, Miguel Ángel; Ciria de Pablo, Cristina; Ibáñez Sanz, Patricia; Sánchez Luis, Carlos; Pizarro Portillo, Alberto; Suárez Fernández, Carmen.
Med. clín (Ed. impr.) ; 129(7): 241-246, jul. 2007. tab
Artículo en Es | IBECS (España) | ID: ibc-057927

Documentos relacionados

  1. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol.
  2. In patients with stable CVD receiving statins, evolocumab reduced acute arterial events across all vascular territories.
  3. Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
  4. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
  5. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis.
  6. CETP Inhibitors: Should We Continue to Pursue This Pathway?
  7. PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology.
  8. Monitoring policy in the context of preventive treatment of cardiovascular disease.
  9. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
  10. PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care.